Evidence map›Paper›PMID 34716958›Full record

ArticleMolecular oncology2022

Nuclear FABP7 regulates cell proliferation of wild-type IDH1 glioma through caveolae formation.

Yoshiteru Kagawa, Banlanjo Abdulaziz Umaru, Masayuki Kanamori, Ryo Zama, Subrata Kumar Shil, Hirofumi Miyazaki, Shuhei Kobayashi, Tunyanat Wannakul, Shuhan Yang, Teiji Tominaga and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Caveolae: Metabolic Platforms at the Crossroads of Health and Disease.International journal of molecular sciences · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. RNA splicing: a dual-edged sword for hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2022
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yoshiteru KagawaDepartment of Organ Anatomy, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID 0000-0003-2963-7905
Banlanjo Abdulaziz UmaruDepartment of Organ Anatomy, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masayuki KanamoriDepartment of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ryo ZamaDepartment of Organ Anatomy, Tohoku University Graduate School of Medicine, Sendai, Japan.
Subrata Kumar ShilDepartment of Organ Anatomy, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hirofumi MiyazakiDepartment of Organ Anatomy, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shuhei KobayashiDepartment of Organ Anatomy, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tunyanat WannakulDepartment of Organ Anatomy, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shuhan YangDepartment of Organ Anatomy, Tohoku University Graduate School of Medicine, Sendai, Japan.
Teiji TominagaDepartment of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yuji OwadaDepartment of Organ Anatomy, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isocitrate dehydrogenase 1 (IDH1) is a key enzyme in cellular metabolism. IDH1 mutation (IDH1mut) is the most important genetic alteration in lower grade glioma, whereas glioblastoma (GB), the most common malignant brain tumor, often has wild-type IDH1 (IDH1wt). Although there is no effective treatment yet for neither IDH1wt nor IDHmut GB, it is important to note that the survival span of IDH1wt GB patients is significantly shorter than those with IDH1mut GB. Thus, understanding IDH1wt GB biology and developing effective molecular-targeted therapies is of paramount importance. Fatty acid-binding protein 7 (FABP7) is highly expressed in GB, and its expression level is negatively correlated with survival in malignant glioma patients; however, the underlying mechanisms of FABP7 involvement in tumor proliferation are still unknown. In this study, we demonstrate that FABP7 is highly expressed and localized in nuclei in IDH1wt glioma. Wild-type FABP7 (FABP7wt) overexpression in IDH1wt U87 cells increased cell proliferation rate, caveolin-1 expression, and caveolae/caveosome formation. In addition, FABP7wt overexpression increased the levels of H3K27ac on the caveolin-1 promoter through controlling the nuclear acetyl-CoA level via the interaction with ACLY. Consistent results were obtained using a xenograft model transplanted with U87 cells overexpressing FABP7. Interestingly, in U87 cells with mutant FABP7 overexpression, both in vitro and in vivo phenotypes shown by FABP7wt overexpression were disrupted. Furthermore, IDH1wt patient GB showed upregulated caveolin-1 expression, increased levels of histone acetylation, and increased levels of acetyl-CoA compared with IDH1mut patient GB. Taken together, these data suggest that nuclear FABP7 is involved in cell proliferation of GB through caveolae function/formation regulated via epigenetic regulation of caveolin-1, and this mechanism is critically important for IDH1wt tumor biology.

Indexed as

Brain NeoplasmsGlioblastomaGliomaAcetyl Coenzyme ACaveolaeCaveolin 1Cell Line, TumorCell ProliferationEpigenesis, GeneticFatty Acid-Binding Protein 7HumansIsocitrate DehydrogenaseMutationTumor Suppressor ProteinsAcetyl Coenzyme ACaveolin 1FABP7 protein, humanFatty Acid-Binding Protein 7IDH1 protein, humanIsocitrate DehydrogenaseTumor Suppressor Proteinsacetyl-CoAcaveolaecaveolin-1fatty acid-binding protein 7isocitrate dehydrogenase 1

Identifiers

PMID34716958
PMCPMC8732344
OpenAlexW3211009067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.